Latest news from Altheus Therapeutics on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/altheus-therapeutics-completes-treatment-portion-of-za201-a-phase-2-trial-of-zoenasa-for-ulcerative-colitis/?sc=rsin /articles/altheus-therapeutics-completes-treatment-portion-of-za201-a-phase-2-trial-of-zoenasa-for-ulcerative-colitis/?sc=rsin Wed, 26 Feb 2014 09:00:00 EST Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa(r) Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis. Altheus Therapeutics /articles/altheus-therapeutics-announces-the-uspto-has-awarded-the-zoenasa-patent-for-oral-combination-therapy/?sc=rsin /articles/altheus-therapeutics-announces-the-uspto-has-awarded-the-zoenasa-patent-for-oral-combination-therapy/?sc=rsin Wed, 29 Jan 2014 11:00:00 EST /PRNewswire/ -- Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine). Combination therapy patents are uncommon and under-appreciated in the pharmaceutical industry because the Patent Office requires surprising, unexpected, or synergistic benefits from combining active ingredients into a single formulation. Altheus' success in procuring the strong and diverse patents for Zoenasa, including this most recent oral combination therapy patent, stems from rigorous studies demonstrating highly statistically significant synergy between Zoenasa's two components. Altheus Therapeutics